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Background: Adverse reactions to iodinated and gadolinium contrast media are an important clinical issue.
Although some guidelines have proposed oral steroid premedication protocols to prevent adverse reactions, some
patients may have reactions to contrast media in spite of premedication (breakthrough reaction; BTR).
The purpose of this study was to assess the frequency, type and severity of BTR when following an oral steroid
premedication protocol.
Methods: All iodinated and gadolinium contrast-enhanced radiologic examinations between August 2011 and
February 2013 for which the premedication protocol was applied in our institution were assessed for BTRs.
Results: The protocol was applied to a total of 252 examinations (153 patients, ages 15–87 years; 63 males, 90
females). Of these, 152 were for prior acute adverse reactions to contrast media, 85 were for a history of bronchial
asthma, and 15 were for other reasons. There were 198 contrast enhanced CTs and 54 contrast enhanced MRIs.
There were nine BTR (4.5%) for iodinated contrast media, and only one BTR (1.9%) for gadolinium contrast media:
eight were mild and one was moderate. No patient who had a mild index reaction (IR) had a severe BTR.
Conclusion: Incidence of BTRs when following the premedication protocol was low. This study by no means proves
the efficacy of premedication, but provides some support for following a premedication protocol to improve safety of
contrast-enhanced examinations when prior adverse reactions are mild, or when there is a history of asthma.
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Intravenous contrast media are essential for modern
medical imaging. Two of the most common intravenous
contrast media are iodinated contrast media for com-
puted tomography (CT) and angiography, and gadolin-
ium contrast media for magnetic resonance imaging
(MRI). These contrast media are relatively safe, but ad-
verse reactions to contrast media are still an important
clinical issue. Patient-related risk factors for acute ad-
verse reactions to these contrast media have been estab-
lished, i.e. 1) a history of previous acute reaction to
contrast media, 2) a history of asthma, and 3) a history* Correspondence: akiko_jingu@yahoo.co.jp
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reproduction in any medium, provided the orof allergies requiring medical treatment [1,2]. Although
some guidelines have proposed oral steroid premedica-
tion protocols to prevent adverse reactions [1,2], some
patients may have reactions to contrast media in spite of
premedication (breakthrough reaction; BTR) [3-5]. The
efficacy of premedication is still unclear, and in particu-
lar the frequency of BTR after gadolinium contrast
media administration has been little reported.
In our institution, as a general rule, patients with a his-
tory of severe or moderate adverse reactions to contrast
do not undergo contrast-enhanced examinations. Those
with a history of mild reactions or a history of bronchial
asthma will undergo contrast-enhanced examinations
only when they have received oral premedication.
The purpose of this study was to assess the frequency,
type and severity of BTR, following oral steroid pre-
medication protocol.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Patients
All patients who underwent contrast-enhanced examina-
tions using iodinated and gadolinium contrast media
between August 2011 and February 2013 while following
our institution’s premedication protocol were evaluated by
retrospective chart review. Patients’ demographic data,
history of adverse reactions (type and severity) to contrast
media, history of asthma, history of other allergic reac-
tions, reason for adopting premedication protocol, con-
trast media used, amount of contrast media, and type,
severity, treatment and outcomes of BTR (if any) were
collected. Institutional review board (Gunma University
Graduate School of Medicine Human Research Committee)
approval was obtained, and it was determined that
informed patient consent was not required because of the
retrospective nature of this study.
We did not include interventional radiology cases. The
frequent use of additional drugs (including embolization
materials, chemotherapeutic agents and sedatives), and
the complexity of the procedures make it difficult to
determine the cause of any adverse reactions.
All contrast-enhanced CT and MRI examinations
following the premedication protocol were recorded
using forms designated by our department. All adverse
reactions occurring in our department were evaluated
by a radiologist in charge, and the type, severity, treat-
ment and outcome of the reactions were recorded. The
type and severity of acute reactions were graded using
an original grading system based on the ACR Manual
on Contrast Media Version 7 [1] and ESUR Guidelines
on Contrast Media Version 7 [2]. The grading system
is as follows:
Mild: nausea, mild vomiting, urticarial rash, itching,
mild laryngeal discomfort
Moderate: severe vomiting, severe urticarial rash,
bronchospasm, facial and/or laryngeal edema,
vasovagal reaction
Severe: hypotensive shock, respiratory arrest, cardiac
arrest, convulsions.
Both index reaction (IR) (the reaction prompting the
use of oral premedication) and BTR were recorded using
the same grading system.
If premedication was administered according to the
protocol of our department, the repeated reaction was
considered a BTR. When an acute adverse reaction
occurred, patients were usually observed in our hospital
for at least one hour.
Premedication protocol
Our departmental policy for the premedication protocol
for contrast-enhanced examinations is based on theACR Manual on Contrast Media Version 7 [1] and
ESUR Guidelines on Contrast Media Version 7 [2]. The
former does not differentiate severity and simply states
history of reaction as a risk factor. The latter, on the
other hand, states moderate to severe reactions as risk
factors, and does not consider mild reactions an indica-
tion for premedication. Our own original premedication
protocol is followed for patients with a history of mild
adverse reactions, a history of bronchial asthma regard-
less of severity, or a history of allergies requiring medical
treatment. The protocol is as follows:
1. Patients with a history of mild adverse reactions,
history of bronchial asthma (regardless of severity),
or a history of allergies requiring medical treatment
will undergo contrast enhanced examinations if
premedicated as follows:
1) Methylprednisolone (Medorol: Pfizer Co., Tokyo,
Japan) 32 mg p.o. 12 and 2 hours prior to
administration of contrast.
2. Patients with a history of moderate or severe adverse
reactions to contrast media should not undergo
contrast-enhanced examinations, with or without
premedication.
2) Diphenhydramine chlorate (Restamin: Kowa Co.,
Tokyo, Japan) 50 mg p.o 1 hour prior to
administration of contrast. This is optional, and
contraindicated for glaucoma and benign
prostatic hypertrophy.
Patients with a history of moderate or severe adverse re-
actions to contrast media are not the target of the protocol,
and usually do not undergo a contrast-enhanced examin-
ation. In our hospital, the decision to perform the protocol
is made by a physician who orders a radiological examin-
ation, if necessary after discussion with a radiologist.
Contrast media
In our hospital, high-osmolality contrast media (HOCM)
is no longer used, and all contrast-enhanced CT are per-
formed using low-osmolality contrast media (LOCM).
We use four kinds of iodinated contrast media. They are
Iopamidol (Iopamiron; Bayer Co. Ltd., Osaka, Japan),
Iomeprol (Iomeron; Eisai Co. Ltd., Tokyo, Japan), Iohexial
(Omnipaque; Daiichi-Sankyo Co. Ltd., Tokyo, Japan), and
Ioversol (Optiray; Daiichi-Sankyo Co. Ltd., Tokyo, Japan).
Three kinds of gadolinium contrast media are used,
which are Gadoterate meglumine (Magnescope; Terumo
Co. Ltd., Tokyo, Japan), Gadteridol (ProHance; Eisai Co.
Ltd., Tokyo, Japan), and Gadopentetate dimeglumine
(Magnevist; Bayer Co. Ltd., Osaka, Japan). Selection of
contrast media was based on the purpose of the examin-
ation and the patient’s weight. Although there are few
data to support changing the contrast media to decrease
Table 2 Severity of BTR to iodinated contrast media in
premedicated asthmatic patients (CT)
Breakthrough reaction (BTR)
Mild Moderate Severe
Asthma (n =64) 1 0 0
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history of prior allergic-like reactions to iodinated con-
trast media, we usually change the contrast media ad-
ministered in such cases.
Data analysis
The incidence of BTR was calculated, and the type and
severity of BTR were compared to those of IRs.
Results
A total of 252 examinations using iodinated contrast
media (n =198, CTs) or gadolinium contrast media
(n =54, MRIs) were performed following the premedica-
tion protocol on 153 patients (63 males, 90 females, age
15–87 years) during the study period. During this time,
a total of 61,810 examinations (41,388 CTs, 20,422
MRIs) were performed in our institution.
The total number of adverse reactions to iodinated con-
trast media during this period (with and without premedica-
tion) was 110, or 0.27% of the total number of contrast
enhanced CTs. The total number of adverse reactions to
gadolinium contrast media during this period was 26 or
0.13% of the total number of contrast enhanced MRIs.
BTR of iodinated contrast media (CT)
The reasons for following the premedication protocol
for 198 examinations in 125 patients using iodinated
contrast media and the severity of BTRs are summarized
on Tables 1 and 2. The reasons for following the pre-
medication protocol were a history of acute adverse re-
actions to iodinated contrast media in 117 examinations,
a history of acute adverse reactions to gadolinium con-
trast in six examinations, a history of asthma in 64
examinations, and suspected delayed adverse reaction to
iodinated contrast media in 11 examinations. The prior
adverse reactions were mild for 117 examinations, mod-
erate for six, and severe for zero. Among these 198
examinations in 125 patients, there were BTRs in nine
examinations (4.5%; 9/198 examinations, Table 3): eight
were mild, one was moderate.
The patient (No. 1) who experienced a mild BTR
presented with urticarial rash upon administration ofTable 1 Severity of IR and severity of BTR to iodinated
contrast media (CT)
Initial reaction (IR; n =134) Breakthrough reaction (BTR)
Mild Moderate Severe
Iodine Mild (n =113) 7 1 0
Moderate (n =4) 0 0 0
Gadolinium Mild (n =4) 0 0 0
Moderate (n =2) 0 0 0
Others* (n =11) 0 0 0
*Suspected delayed adverse reactions to iodinated contrast media (n =11).premedication, and the rash worsened after administra-
tion of contrast, so it was difficult to tell whether pre-
medication or contrast was the cause of the rash.
BTR of gadolinium contrast media
The reason for following the premedication protocol for
54 examinations in 40 patients using gadolinium con-
trast media, and the severity of BTRs are summarized in
Tables 4 and 5. The reasons for following the premedica-
tion protocol were a history of acute adverse reactions
to iodinated contrast media in 23 examinations, a history
of acute adverse reactions to gadolinium contrast media
in six examinations, a history of asthma in 21 examina-
tions, and others in four examinations. The prior acute
adverse reactions to gadolinium were all mild, but the
prior acute adverse reactions to iodinated contrast media
were moderate for two, and severe for six examinations.
Among the 54 examinations using gadolinium contrast
media after premedication, there was mild BTR in only
one examination (1.9%; 1/54 examinations, Tables 4 and
5). This patient received premedication because of a
history of bronchial asthma, and the BTR was nausea.
Discussion
Acute adverse reactions to contrast media will occur at a
certain rate. Non-ionic iodinated contrast is said to have
an adverse reaction rate of about 0.6 to 3.1% [6-10]. This
rate is said to be about 0.07 to 0.67% for gadolinium
contrast media [6-9].
The ACR Manual on Contrast Media [1] and EUSR
Guidelines on Contrast Media [2] recommend pre-
medication for patients at risk for adverse reactions to
contrast, but the definition of at-risk has some variation
among protocols and studies. The ACR Manual states
patients with a history of adverse reactions should be
premedicated, but does not elaborate on the degree of
the reaction. The ESUR Guidelines, on the other hand,
includes patients with a history of moderate or severe
reactions. When following the ESUR Guidelines, patients
with history of mild reactions to contrast undergo con-
trast enhanced examinations without premedication.
(We chose to follow and reference the older versions of
the ACR Manual and ESUR Guidelines, as these were
the ones available when we created our protocol and
conducted our study). Our own original institutional
protocol includes patients who have a history of mild
adverse reactions to contrast, a history of asthma, or a






Severity Nature Severity Nature
1* M/62 1 Mild urticaria, itching Mild urticaria, itching
2 M/61 1 Mild rash Mild nausea
3 M/67 1 Mild mild laryngeal discomfort - asthma
4 F/41 1 Mild nausea Mild nausea
5 F/58 2 Mild nausea/nausea Mild nausea
6 M/70 1 Mild nausea Mild nausea
7 F/64 1 Mild urticaria Mild urticaria
8 F/67 1 Moderate severe urticarial rash/facial edema Mild discomfort
*This patient presented with urticarial rash upon administration of premedication, and the rash worsened after administration of contrast.
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patients requiring premedication. Patients with a history
of moderate or severe reactions to contrast are advised
not to undergo a contrast-enhanced study and consider
an alternative examination.
Acute adverse reactions are known to occur even
when the patient is premedicated. Such reactions are
called BTRs [3-5,11], while the initial adverse reaction
occurring without premedication is called the index
reaction (IR) [3]. The term BTR has been used in the
literature to indicate a reaction that occurs after contrast
administration in patients who have been premedicated
with corticosteroids [3-5,11]. Davenport et al. defined to
this term more restrictively to refer to only those allergic-
like reactions that occurred in premedicated patient with a
history of prior allergic-like reactions to iodinated contrast
media [3]. In our study, we used this term to refer to acute
adverse reactions that occurred in a premedicated patient
regardless of the indication for premedication (whether it
was a history of prior acute adverse reactions to contrast
media, a history of bronchial asthma, or a history of aller-
gies requiring medical treatment).
In this study, the total rate of BTRs was 4.0%: the rate
of BTRs for iodinated contrast media was 4.5%, and the
rate of BTRs for gadolinium contrast media was only
1.9%. Nearly all were mild BTRs, but there was oneTable 4 Severity of IR and severity of BTR to gadolinium
contrast media
Initial reaction (IR; n =33) Breakthrough reaction (BTR)
Mild Moderate Severe
Iodine Mild (n =15) 0 0 0
Moderate (n =2) 0 0 0
Severe (n =6) 0 0 0
Gadolinium Mild (n =6) 0 0 0
Others* (n =4) 0 0 0
*In two patients, drug eruption was clinically suspected, but the causal
medication was not identified. In another two patients, mild delayed reaction
to iodinated contrast media was clinically suspected.moderate BTR. There were no patients who had a mild
IR followed by a severe BTR.
Davenport et al. reported that for iodinated contrast
media, the rate of BTRs was 18% [3], while Kim et al.
reported a rate of 16.7% [11]. The results of our current
study showed a somewhat lower rate. The reason for the
lower rate of BTRs in our study is not entirely clear, but
a possible explanation is the smaller percentage of exam-
inations with a prior reaction that was moderate or se-
vere. In the current study, only 4.2% (9/214) of iodinated
contrast-enhanced examinations were performed for
patients with moderate IRs for iodinated or gadolinium
contrast media, and no patients in our study had severe
IRs. Our current departmental policy is to premedicate
patients with a history of mild adverse reactions to con-
trast, and to try to avoid its use entirely in patients whose
prior reactions are moderate or severe. Ten percent (106/
1044) and 43% (13/30) of the patients in Davenport et al.
[3] and Kim et al. [11] had moderate or severe IRs. In our
institution, we are frequently consulted for alternative ex-
aminations for such patients, and recommend ultrasound
or MRI without contrast (or with contrast for patients
whose only reason for concern is a history of adverse
reactions to iodinated contrast media), or nuclear medicine
examinations such as PET. Japanese physicians tend to be
extremely wary of acute adverse effects to contrast
enhanced examinations, and it is likely that they will avoid
ordering additional contrast enhanced examinations with
or without premedication for a patient with a history of ad-
verse reactions with contrast, even when said reactions are
mild. Considering this tendency, we did not expect six




Asthma (n =21) 1 0 0
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of moderate reaction to gadolinium contrast media to
receive contrast with premedication. Our current
hospital policy is for the referring clinician to decide the
indication for contrast use and also premedication. The
radiology department may make recommendations to
abstain from contrast use, but the patient and referring
clinician make the final decision.
Another reason for our lower rate of BTRs may be our
definition of BTRs. In this study, we defined BTR as
acute reactions that occurred after premedication not
only in patients with a prior history of reaction to con-
trast, but also patients with history of asthma or other
allergies requiring medical treatment.
BTRs exceeded IRs in 11.1% (1/9) of iodinated contrast-
enhanced examinations in our study. Freed et al. report
BTRs exceeding IRs in 11% [5], and Kim et al. report 0%
[11]. There have, however, been no reports of a mild IR
followed by a severe BTR, and there were no such patients
in our study, either.
There have been few reports on BTRs for gadolinium
contrast media. Dillman et al. [9] reported nine BTRs
among 78,353 examinations. In their study, however, the
total number of patients undergoing premedication was
unknown, thus the incidence of BTRs after premedica-
tion could not be calculated. In our study, we observed a
total of 54 premedicated examinations, and there was
mild BTR in only one examination (1.9%). In 23 of 54
examinations, premedication was administered because
of a history of acute adverse reaction to iodinated contrast
media. Although, to our knowledge, there have been no
reports suggesting cross-reactivity between iodinated and
gadolinium contrast media, a history of acute adverse re-
action to iodinated contrast media can arguably be consid-
ered a history of allergy requiring treatment. In our study,
there was no BTR in patients who were premedicated
because of IRs for iodinated contrast media.
Bronchial asthma is a known risk factor for adverse re-
actions to contrast media [1,2,12]. In the current study,
the incidence of BTR after premedication for patients
with a history of bronchial asthma was low (2.4%; 2/85)
regardless of severity of asthma: one patient receiving
iodinated contrast media complained of mild laryngeal
discomfort and another receiving gadolinium contrast
media experienced nausea.
A limitation of this study was that since this was a retro-
spective study, there was no control group consisting of
patients undergoing contrast-enhanced study without pre-
medication. Since performing a contrast-enhanced exam-
ination without premedication on a patient with known
risk factors can arguably be considered unethical, it would
probably be difficult to conduct a study with a control
group, even as a prospective study. This makes it very dif-
ficult to provide evidence that premedication indeedreduces the rate of adverse reactions. Another limitation
of this study was that not all patients experiencing an IR
underwent additional contrast enhanced examinations.
Since the decision to use contrast was made by the refer-
ring physician, there may be a selection bias.
Conclusions
The incidence of BTR after premedication was low. When
prior adverse reactions are mild, or when there is a history
of asthma, following a premedication protocol may make
it possible to safely perform contrast-enhanced examina-
tions. However, when IR is moderate or severe, contrast
should only be used with extreme caution even with
premedication.
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